GLP-1 Drugs Cut Liver Failure Risk by 42% Compared to Older Diabetes Medications | Research

The takeaway

GLP-1 receptor agonists reduced the risk of hepatic decompensation by 42% compared to sulfonylureas in a large real-world study of 38,524 patients with type 2 diabetes.

HR 0.58 (42% lower risk)
GLP-1 receptor agonists were associated with a 42% lower risk of hepatic decompensation compared to sulfonylureas, with per-protocol analysis showing an even stronger 57% reduction.

What the researchers found

Among 38,524 patients with type 2 diabetes:

- GLP-1RAs reduced hepatic decompensation risk by 42% vs sulfonylureas (HR 0.58, 95% CI 0.38-0.88)

- SGLT2is reduced risk by 35% vs sulfonylureas (HR 0.65, 95% CI 0.43-0.98)

- GLP-1RAs reduced risk by 41% vs DPP4is (HR 0.59, 95% CI 0.39-0.89)

- Per-protocol analysis showed even stronger GLP-1RA protection (HR 0.43, 95% CI 0.22-0.82, a 57% risk reduction)

- No significant difference between GLP-1RAs and SGLT2is

- 1,743 hepatic decompensation events occurred over median 3.1 years follow-up

Why it matters

Many patients with type 2 diabetes have undiagnosed fatty liver disease that can progress to serious liver failure. This study provides real-world evidence that GLP-1 peptide drugs don't just control blood sugar — they may also significantly protect the liver. For clinicians choosing between diabetes medications, this adds liver protection as another reason to prefer GLP-1 agonists, especially in patients with metabolic liver disease risk.

How the study worked

Retrospective new-user cohort study emulating a target trial using electronic health records from Mass General Brigham (2012-2024). 38,524 adults with T2DM who newly started one of four drug classes were included. Propensity score overlap weighting was used for covariate balance. Both intention-to-treat and per-protocol analyses were performed, with multiple sensitivity analyses.

What this study cannot tell us

This is an observational retrospective study, not a randomized trial, so confounding cannot be entirely eliminated despite propensity score methods. The study used electronic health records from a single health system (Mass General Brigham), which may not represent all patient populations. Specific GLP-1RA drugs were not compared individually. The mechanisms driving liver protection were not investigated.

How to read the evidence

This is a large retrospective cohort study using target trial emulation methodology — a rigorous approach for observational data. With 38,524 patients and multiple sensitivity analyses, the findings are robust, though a randomized trial would provide definitive evidence.

When this study was published

Published in 2025 using data through June 2024, this is among the most current evidence on GLP-1 drug liver protection, from one of the world's leading academic medical systems.

The bigger picture

The expanding benefits of GLP-1 peptide drugs continue to extend beyond glycemic control. Evidence for cardiovascular protection, kidney protection, and now liver protection positions these drugs as potential multi-organ protective agents for patients with metabolic disease. This study adds to the growing case that GLP-1 agonists should be first-line therapy for type 2 diabetes, not just for sugar control but for comprehensive organ protection.

Questions still open

Which specific GLP-1 receptor agonists provide the strongest liver protection?
What biological mechanisms drive GLP-1RA-associated liver protection — is it primarily through weight loss, direct hepatic effects, or reduced inflammation?
Would combining GLP-1RAs with SGLT2is provide even greater liver protection than either alone?

Common questions

What is hepatic decompensation and why does it matter?

Hepatic decompensation means the liver can no longer function well enough to keep up with the body's needs. It includes serious complications like fluid accumulation in the abdomen, confusion from liver failure, and internal bleeding. It's a life-threatening stage of liver disease that often requires hospitalization and can lead to the need for a liver transplant.

Should I switch from my current diabetes medication to a GLP-1 drug for liver protection?

This study provides evidence that GLP-1 drugs may protect the liver, but medication decisions should always be made with your doctor based on your complete health picture. If you have type 2 diabetes along with risk factors for liver disease (like obesity or fatty liver), this evidence supports discussing GLP-1 receptor agonists as a preferred treatment option with your healthcare provider.

Read the original research

Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation.

JHEP reports : innovation in hepatology, 7(12), 101624

View on PubMed ↗Publisher’s paper ↗

Citation

Choi, Jonggi; Verma, Ana; Nguyen, Vy H; Przybyszewski, Eric; Song, Jiunn; Carroll, Allison; Michta, Megan; Almazan, Erik; Simon, Tracey G; Chung, Raymond T. (2025). Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation.. JHEP reports : innovation in hepatology, 7(12), 101624. https://doi.org/10.1016/j.jhepr.2025.101624